IDH1 and oligodendroglioma: Specifically, there is also genetic and epigenetic heterogeneity in IDH-mt astrocytoma and oligodendroglioma grade 2, however, the new version of the WHO CNS tumor classification does not provide updated detailed molecular variance reflecting clinical behaviors regarding such tumors.